Response gene to complement 32 deficiency causes impaired placental angiogenesis in mice

Cardiovascular Research

Volumn 99, Issue 4, 2013, Pages 632-639

  Cui, Xiao Bing ^a   Guo, Xia ^a   Chen, Shi You ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Angiogenesis; Foetal growth restriction; Placental growth factor; Response gene to complement 32; Vascular endothelial growth factor receptor

Indexed keywords

ANGIOGENIC FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLACENTAL GROWTH FACTOR; PYRROLIDINE DITHIOCARBAMATE; RESPONSE GENE TO COMPLEMENT 32; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY SIZE; CELL PROLIFERATION; CONTROLLED STUDY; DEVELOPMENTAL GENE; DOWN REGULATION; EMBRYO; EMBRYO DEVELOPMENT; EMBRYO GROWTH; EMBRYONIC STEM CELL; EMERGENCY CONTRACEPTION; ENDOTHELIUM CELL; EXON; FEMALE; FETOPLACENTAL UNIT; FETUS; FETUS CIRCULATION; GENE DELETION; GENE SILENCING; GROWTH INHIBITION; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTRAUTERINE GROWTH RETARDATION; MALE; MOUSE; NEURAL TUBE; NONHUMAN; PLACENTA DEVELOPMENT; PLACENTAL ANGIOGENESIS; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TROPHOBLAST; WESTERN BLOTTING; WILD TYPE; YOLK SAC;

ANGIOGENESIS; FOETAL GROWTH RESTRICTION; PLACENTAL GROWTH FACTOR; RESPONSE GENE TO COMPLEMENT 32; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR;

ANIMALS; CELL PROLIFERATION; FEMALE; FETAL DEVELOPMENT; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; NF-KAPPA B; NUCLEAR PROTEINS; PLACENTA; PREGNANCY; PREGNANCY PROTEINS; TROPHOBLASTS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84883215682     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt121     Document Type: Article

References (42)

1. Cetin I, Foidart JM, Miozzo M, Raun T, JanssonT, TsatsarisVet al. Fetal growth restriction: a workshop report. Placenta 2004;25:753-757.
2. Gardosi J. Clinical strategies for improving the detection of fetal growth restriction. Clin Perinatol 2011;38:21-31.
3. Gerber S, Hohlfeld P, Viquerat F, Tolsa JF, Vial Y. Intrauterine growth restriction and absent or reverse end-diastolic blood flow in umbilical artery (Doppler class II or III): a retrospective study of short-and long-term fetal morbidity and mortality. Eur J Obstet Gynecol Reprod Biol 2006;126:20-26.
4. Barker DJ. Adult consequences of fetal growth restriction. Clin Obstet Gynecol 2006;49: 270-283.
5. Regnault TR, Galan HL, Parker TA, Anthony RV. Placental development in normal and compromised pregnancies-A review. Placenta 2002;23 (Suppl. A):S119-S129.
6. Watson ED, Cross JC. Development of structures and transport functions in the mouse placenta. Physiology (Bethesda) 2005;20:180-193.
7. Charnock-Jones DS, Kaufmann P, MayhewTM. Aspects of human fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation. Placenta 2004;25:103-113.
8. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2: 795-803.
9. Grazul-BilskaAT, Borowicz PP, Johnson ML, Minten MA, Bilski JJ,Wroblewski Ret al. Placental development during early pregnancy in sheep: vascular growth and expression of angiogenic factors in maternal placenta. Reproduction 2010;140:165-174.
10. Badea TC, Niculescu FI, Soane L, Shin ML, Rus H. Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. J Biol Chem 1998;273:26977-26981.
11. Li F, Luo Z,HuangW, Lu Q, Wilcox CS, Jose PAet al. Response gene to complement 32, a novel regulator for transforming growth factor-beta-induced smooth muscle differentiation of neural crest cells. J Biol Chem 2007;282:10133-10137.
12. Huang WY, Li ZG, Rus H,Wang X, Jose PA, Chen SY. RGC-32 mediates transforming growth factor-beta-induced epithelial-mesenchymal transition in human renal proximal tubular cells. J Biol Chem 2009;284:9426-9432.
13. Guo X, Jose PA, Chen SY. Response gene to complement 32 interacts with Smad3 to promote epithelial-mesenchymal transition of human renal tubular cells. Am J Physiol Cell Physiol 2011;300:C1415-C1421.
14. AnX, JinY,GuoH, FooSY, Cully BL,WuJ et al. Response gene to complement 32, a novel hypoxia-regulated angiogenic inhibitor. Circulation 2009;120:617-627.
15. Fosbrink M, Cudrici C, Tegla CA, Soloviova K, Ito T, Vlaicu S et al. Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells. Exp Mol Pathol 2009;86:87-94.
16. Wang JN, Shi N, Xie WB, Guo X, Chen SY. Response gene to complement 32 promotes vascular lesion formation through stimulation of smooth muscle cell proliferation and migration. Arterioscler Thromb Vasc Biol 2011;31:e19-e26.
17. Cui XB,Wang C, Li L, Fan D, Zhou Y,WuDet al. Insulin decreases myocardial adiponectin receptor 1 expression via PI3K/Akt and FoxO1 pathway. Cardiovasc Res 2012;93: 69-78.
18. Shi N, Xie WB, Chen SY. Cell division cycle 7 is a novel regulator of transforming growth factor-beta-induced smooth muscle cell differentiation. J Biol Chem 2012;287: 6860-6867.
19. Detmar M, Brown LF, Schon MP, Elicker BM, Velasco P, Richard L et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998;111:1-6.
20. Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, Tatangelo L et al. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci 2002;115:2559-2567.
21. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998;282:468-471.
22. Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC, Tsichlis PN. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell 2011;43:285-298.
23. Yang QC, Zeng BF, Shi ZM, Dong Y, Jiang ZM, Huang J et al. Inhibition of hypoxia-induced angiogenesis by trichostatinAvia suppression of HIF-1a activity in human osteosarcoma. J Exp Clin Cancer Res 2006;25:593-599.
24. Yu JX, Cui L, Zhang QY, Chen H, Ji P,Wei HJ et al. Expression of NOS and HIF-1alpha in human colorectal carcinoma and implication in tumor angiogenesis.World J Gastroenterol 2006;12:4660-4664.
25. Kashif M, Hellwig A, Kolleker A, Shahzad K,Wang H, Lang S et al. p45NF-E2 represses Gcm1 in trophoblast cells to regulate syncytium formation, placental vascularization and embryonic growth. Development 2011;138:2235-2247.
26. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ Res 2007;100:782-794.
27. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-371.
28. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M,WuXF, Breitman ML et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376: 62-66.
29. Yang S, Xin X, Zlot C, Ingle G, Fuh G, Li B et al. Vascular endothelial cell growth factordriven endothelial tube formation is mediated by vascular endothelial cell growth factor receptor-2, a kinase insert domain-containing receptor. Arterioscler Thromb Vasc Biol 2001;21:1934-1940.
30. Korpisalo P, Rissanen TT, Bengtsson T, Liimatainen T, Laidinen S, KarvinenHet al. Therapeutic angiogenesis with placental growth factor improves exercise tolerance of ischaemic rabbit hindlimbs. Cardiovasc Res 2008;80:263-270.
31. Athanassiades A, Lala PK. Role of placenta growth factor (PIGF) in human extravillous trophoblast proliferation, migration and invasiveness. Placenta 1998;19:465-473.
32. Illi B, Puri P, Morgante L, Capogrossi MC, Gaetano C. Nuclear factor-kappaB and cAMP response element binding protein mediate opposite transcriptional effects on the Flk-1/KDR gene promoter. Circ Res 2000;86:E110-E117.
33. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380: 439-442.
34. Ferrara N, GerberHP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676.
35. Koolwijk P, Peters E, van der Vecht B, Hornig C,Weich HA, Alitalo Ket al. Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro. Angiogenesis 2001;4:53-60.
36. Khaliq A, Li XF, Shams M, Sisi P, Acevedo CA, Whittle MJ et al. Localisation of placenta growth factor (PIGF) in human term placenta. Growth Factors 1996;13:243-250, color plates I-II,pre bk cov.
37. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003;1:1356-1370.
38. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7: 575-583.
39. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
40. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 1997;272:23659-23667.
41. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004;95:884-891.
42. Li Z, Xie WB, Escano CS, Asico LD, Xie Q, Jose PA et al. Response gene to complement 32 is essential for fibroblast activation in renal fibrosis. J Biol Chem 2011;286: 41323-41330.